Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment

被引：13
作者：
Gevaert, Thomas [1 ,2 ]
Montironi, Rodolfo [3 ]
Lopez-Beltran, Antonio [4 ,5 ]
Van Leenders, Geert [6 ]
Allory, Yves [7 ]
De Ridder, Dirk [8 ]
Claessens, Frank [9 ]
Kockx, Mark [10 ]
Akand, Murat [11 ]
Joniau, Steven [8 ]
Netto, George [12 ]
Libbrecht, Louis [13 ]
机构：
[1] Katholieke Univ Leuven, Lab Expt Urol, Organ Syst, Leuven, Belgium
[2] AZ Klina, Dept Pathol, Brasschaat, Belgium
[3] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy
[4] Fac Med, Dept Surg & Pathol, Anat Pathol Unit, Cordoba, Spain
[5] Champalimaud Clin Ctr, Lisbon, Portugal
[6] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands
[7] Univ Paris Est Creteil Val de Marne UPEC, Hop Henri Mondor, Fac Med, Serv Anat Pathol, Creteil, France
[8] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[9] Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium
[10] HistoGeneX, Dept Mol Pathol, Antwerp, Belgium
[11] Selcuk Univ, Sch Med, Dept Urol, Konya, Turkey
[12] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[13] Univ Clin St Luc, Dept Pathol, Sint Lambrechts Woluwe, Belgium
来源：
SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷
关键词：
Immunotherapy; Bladder; Kidney; Prostate; Biomarkers; RENAL-CELL CARCINOMA; RESISTANT PROSTATE-CANCER; MISMATCH REPAIR GENES; METASTATIC UROTHELIAL CARCINOMA; INVASIVE BLADDER-CANCER; UPPER URINARY-TRACT; IMMUNE CHECKPOINT INHIBITORS; CISPLATIN-BASED CHEMOTHERAPY; LYNCH SYNDROME; ANDROGEN RECEPTOR;
D O I：
10.1016/j.semcancer.2017.10.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.
引用
收藏
页码：216 / 227
页数：12
相关论文
共 177 条
  • [1] The Molecular Taxonomy of Primary Prostate Cancer
    Abeshouse, Adam
    Ahn, Jaeil
    Akbani, Rehan
    Ally, Adrian
    Amin, Samirkumar
    Andry, Christopher D.
    Annala, Matti
    Aprikian, Armen
    Armenia, Joshua
    Arora, Arshi
    Auman, J. Todd
    Balasundaram, Miruna
    Balu, Saianand
    Barbieri, Christopher E.
    Bauer, Thomas
    Benz, Christopher C.
    Bergeron, Alain
    Beroukhim, Rameen
    Berrios, Mario
    Bivol, Adrian
    Bodenheimer, Tom
    Boice, Lori
    Bootwalla, Moiz S.
    dos Reis, Rodolfo Borges
    Boutros, Paul C.
    Bowen, Jay
    Bowlby, Reanne
    Boyd, Jeffrey
    Bradley, Robert K.
    Breggia, Anne
    Brimo, Fadi
    Bristow, Christopher A.
    Brooks, Denise
    Broom, Bradley M.
    Bryce, Alan H.
    Bubley, Glenn
    Burks, Eric
    Butterfield, Yaron S. N.
    Button, Michael
    Canes, David
    Carlotti, Carlos G.
    Carlsen, Rebecca
    Carmel, Michel
    Carroll, Peter R.
    Carter, Scott L.
    Cartun, Richard
    Carver, Brett S.
    Chan, June M.
    Chang, Matthew T.
    Chen, Yu
    [J]. CELL, 2015, 163 (04) : 1011 - 1025
  • [2] Biological determinants of bladder cancer gene expression subtypes
    Aine, Mattias
    Eriksson, Pontus
    Liedberg, Fredrik
    Sjodahl, Gottfrid
    Hoglund, Mattias
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [3] BCG immunotherapy of bladder cancer: 20 years on
    Alexandroff, AB
    Jackson, AM
    O'Donnell, MA
    James, K
    [J]. LANCET, 1999, 353 (9165) : 1689 - 1694
  • [4] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [5] A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit
    Anastasopoulou, Eleftheria A.
    Voutsas, Ioannis F.
    Keramitsoglou, Theodora
    Gouttefangeas, Cecile
    Kalbacher, Hubert
    Thanos, Anastasios
    Papamichail, Michael
    Perez, Sonia A.
    Baxevanis, Constantin N.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (09) : 1123 - 1136
  • [6] [Anonymous], 2017, IMPACT TUMOR MUTATIO
  • [7] [Anonymous], J CLIN ONCOL
  • [8] [Anonymous], 2017, EUR UROL S, DOI DOI 10.1016/S1569-9056(17)30236-1
  • [9] [Anonymous], GASTROENTEROLOGY
  • [10] [Anonymous], ASCO
12345678910